Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cell Adhesion Molecules (CAMs) and Extracellular Matrix (ECM) components represent a broad class of molecules essential for maintaining tissue architecture and mediating communication between cells and their environment. CAMs, such as integrins, cadherins, and selectins, are transmembrane proteins that facilitate cell-cell and cell-matrix interactions, playing a pivotal role in the leukocyte adhesion cascade and immune cell recruitment [1][4]. The ECM is a complex non-cellular network consisting of fibrous proteins like collagen and elastin, as well as glycosaminoglycans and proteoglycans, which provide structural support and biochemical cues that regulate cell survival and differentiation [2][5]. In disease states, dysregulation of these components can lead to pathological fibrosis, enhanced tumor metastasis through epithelial-mesenchymal transition, and chronic inflammatory conditions like inflammatory bowel disease [3]. Therapeutic interventions targeting this system include monoclonal antibodies that inhibit specific integrins to treat autoimmune disorders and enzymes designed to remodel the ECM in conditions like Dupuytren's contracture [4]. Given the diversity of this category, it is typically classified as a group of targets rather than a single therapeutic entity [1]. Sources: [1] StatPearls: Cell Adhesion Molecules (https://www.ncbi.nlm.nih.gov/books/NBK541078/) [2] Frantz, C., et al. (2010). The extracellular matrix at a glance. Journal of Cell Science (https://doi.org/10.1242/jcs.023820) [3] Hynes, R. O. (2009). The Extracellular Matrix: Not Just Soft Glue. Science (https://doi.org/10.1126/science.1176009) [4] Ley, K., et al. (2007). Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nature Reviews Immunology (https://doi.org/10.1038/nri2156) [5] UniProt: Extracellular matrix organization (https://www.uniprot.org/keywords/KW-0272)
Inhibition of leukocyte trafficking by blocking integrin-ligand interactions; enzymatic degradation of structural ECM proteins to reduce tissue tension or facilitate drug delivery; blockade of platelet aggregation via integrin inhibition.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cell Adhesion Molecules and Extracellular Matrix Components (CAMs and ECM).